These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 29961057)

  • 1. A Partial Response at Week 4 Can Predict Subsequent Outcome during Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder: A Preliminary Study.
    Nagai G; Mihara K; Kagawa S; Nakamura A; Suzuki T; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 76(4):187-192. PubMed ID: 29961057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder.
    Kagawa S; Mihara K; Suzuki T; Nagai G; Nakamura A; Nemoto K; Kondo T
    Neuropsychobiology; 2017; 75(3):145-150. PubMed ID: 29332095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder.
    Kagawa S; Mihara K; Nakamura A; Nemoto K; Suzuki T; Nagai G; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):730-3. PubMed ID: 24819973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2.
    Nakamura A; Mihara K; Nagai G; Kagawa S; Suzuki T; Nemoto K; Kondo T
    Ther Drug Monit; 2016 Jun; 38(3):379-82. PubMed ID: 26829597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between UGT1A4 and UGT2B7 Polymorphisms and the Steady-State Plasma Concentrations of Lamotrigine in Patients With Treatment-Resistant Depressive Disorder Receiving Lamotrigine as Augmentation Therapy.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2019 Feb; 41(1):86-90. PubMed ID: 30489548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A High Plasma Lamotrigine Concentration at Week 2 as a Risk Factor for Lamotrigine-Related Rash.
    Suzuki T; Mihara K; Nagai G; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Ther Drug Monit; 2020 Aug; 42(4):631-635. PubMed ID: 31985552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability.
    Ivković M; Damjanović A; Jovanović A; Cvetić T; Jasović-Gasić M
    Psychiatr Danub; 2009 Jun; 21(2):187-93. PubMed ID: 19556947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Augmentation Strategies in Major Depression.
    Martiny K
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A factor analytic study in bipolar depression, and response to lamotrigine.
    Mitchell PB; Hadzi-Pavlovic D; Evoniuk G; Calabrese JR; Bowden CL
    CNS Spectr; 2013 Aug; 18(4):214-24. PubMed ID: 23702258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    Solmi M; Veronese N; Zaninotto L; van der Loos ML; Gao K; Schaffer A; Reis C; Normann C; Anghelescu IG; Correll CU
    CNS Spectr; 2016 Oct; 21(5):403-418. PubMed ID: 27686028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
    Nierenberg AA; Ostacher MJ; Calabrese JR; Ketter TA; Marangell LB; Miklowitz DJ; Miyahara S; Bauer MS; Thase ME; Wisniewski SR; Sachs GS
    Am J Psychiatry; 2006 Feb; 163(2):210-6. PubMed ID: 16449473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression.
    Barbee JG; Thompson TR; Jamhour NJ; Stewart JW; Conrad EJ; Reimherr FW; Thompson PM; Shelton RC
    J Clin Psychiatry; 2011 Oct; 72(10):1405-12. PubMed ID: 21367355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of response to electroconvulsive therapy obtained using the three-factor structure of the Montgomery and Asberg Depression Rating Scale for treatment-resistant depressed patients.
    Okazaki M; Tominaga K; Higuchi H; Utagawa I; Nakamura E; Noguchi M; Itaya M; Hashimoto C; Yamaguchi N
    J ECT; 2010 Jun; 26(2):87-90. PubMed ID: 19710622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study.
    Schindler F; Anghelescu IG
    Int Clin Psychopharmacol; 2007 May; 22(3):179-82. PubMed ID: 17414745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bipolar depression: a new role for atypical antipsychotics?
    Keck PE
    Bipolar Disord; 2005; 7 Suppl 4():34-40. PubMed ID: 15948765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the Efficacy of Lamotrigine and the Serum Lamotrigine Level during the Remission Phase of Acute Bipolar II Depression: A Naturalistic and Unblinded Prospective Pilot Study.
    Kikkawa A; Kitamura Y; Aiba T; Hiraki K; Sendo T
    Biol Pharm Bull; 2017; 40(4):413-418. PubMed ID: 28381796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive lamotrigine therapy for patients with bipolar II depression partially responsive to mood stabilizers.
    Chang JS; Moon E; Cha B; Ha K
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Oct; 34(7):1322-6. PubMed ID: 20673782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
    Nakajima S; Uchida H; Suzuki T; Watanabe K; Hirano J; Yagihashi T; Takeuchi H; Abe T; Kashima H; Mimura M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1983-9. PubMed ID: 21889560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of aripiprazole for depressed patients with an inadequate response to antidepressant treatment: a 6-week prospective, open-label, multicenter study.
    Jon DI; Kim DH; Seo HJ; Kwon YJ; Kim MD; Yang JC; Suh HS; Min KJ; Pae CU; Bahk WM
    Clin Neuropharmacol; 2013; 36(5):157-61. PubMed ID: 24045606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts.
    Suppes T; Kroger H; Pikalov A; Loebel A
    J Psychiatr Res; 2016 Jul; 78():86-93. PubMed ID: 27089521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.